ND SB2066

Amends the prior authorization program for medical assistance drug coverage to comply with federal Medicaid requirements under 42 U.S.C. 1396r-8(d)

Prohibits prior authorization for antineoplastic agents (cancer drugs) except to verify the agent is FDA-approved or nationally standard and complies with the Social Security Act; the department cannot prefer one antineoplastic agent over another

Requires the department to provide medical criteria, cost information, and utilization data to a drug use review board for consideration when placing any drug on the prior authorization program

Allows the department to use contractors to collect and analyze documentation and facilitate the prior authorization program

Requires the department to consult with the review board when adopting rules and establish processes allowing prescribers to submit documentation without disrupting patient care